CClinicalTrials.gg
Sign In
CompletedNCT04982263Updated Jul 29, 2021

Blood Coagulation Abnormalities in COVID-19 (Corona Virus Disease-19) Patients

An observational study in Covid19, sponsored by Sohag University. Completed at 2 sites in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-29.

Sponsored by Sohag University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
125
Ages
18 Years and older
Sex
All
01

Study summary

The role of the coagulation parameters in predicting the severity of COVID-19 disease will be assessed

Read the detailed description

In COVID-19 patients the coagulation parameters Prothrombin concentration (PC), Activated Partial Thromboplastin Time (aPTT), D Dimer, Antithrombin III (ATIII) and Fibrinogen are measured and correlation with disease severity is to be investigated

02

Conditions studied

  • Covid19

Browse trials for

03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's enrollment of 125 is below the median of 261 across 3,136 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cases with confirmed COVID 19 disease

Inclusion criteria

● Confirmed cases with COVID 19

Exclusion criteria

Exclusion Criteria:

● Known history of blood coagulopathy disorder

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
125 participants (actual)
Patient registry
No

Groups and cohorts

  • Mild cases

    Patients with confirmed COVID-19 and with mild disease

    Diagnostic Test: Blood coagulation profile

  • Severe cases

    Patients with confirmed COVID-19 and with severe disease

    Diagnostic Test: Blood coagulation profile

Interventions

  • Diagnostic testBlood coagulation profile

    Venous blood sample for measurement of blood coagulation profile

06

What researchers measure

Primary outcomes

  1. correlation of disease severity with results of laboratory test

    The results of blood coagulation profile will be correlated with degree of severity of illness

    Time frame: Baseline results of coagulation profile and baseline disease severity assessment

Secondary outcomes

  1. Agreement of abnormalities in coagulation profile with measured inflammatory markers

    The inflammatory markers will be measured and correlation with abnormalities in coagulation profile will be assessed

    Time frame: baseline measurement of inflammatory markers

07

Study locations

2 sites
  • Sohag University
    Sohag, 82425, Egypt
  • Sohag University
    Sohag, 82524, Egypt
08

References and documents

Publications

  • Fauci AS, Lane HC, Redfield RR. Covid-19 - Navigating the Uncharted. N Engl J Med. 2020 Mar 26;382(13):1268-1269. doi: 10.1056/NEJMe2002387. Epub 2020 Feb 28. No abstract available. PubMed 32109011 ↗
  • Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768. Epub 2020 Mar 13. PubMed 32073213 ↗
  • Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA. Hematological findings and complications of COVID-19. Am J Hematol. 2020 Jul;95(7):834-847. doi: 10.1002/ajh.25829. Epub 2020 May 23. PubMed 32282949 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04982263
Lead sponsor
Sohag University
Responsible party
Hend Mohammed Abdelraheem Esmaeel (assistant professor, Sohag University) — Principal investigator
First posted
Jul 29, 2021
Start date
Feb 1, 2021
Primary completion
May 31, 2021
Completion
May 31, 2021
Last update
Jul 29, 2021

Study contacts

Hend mohamed A Esmaeel, M.D
principal investigator · Sohag Univesity

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

COVID-19→

Other studies from this sponsor

Sohag University

Start the discussion